0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report

Charles G. Moertel, MD; Thomas R. Fleming, PhD; John S. Macdonald, MD; Daniel G. Haller, MD; John A. Laurie, MD; Catherine M. Tangen, MS; James S. Ungerleider, MD; William A. Emerson, MD; Douglass C. Tormey, MD, PhD; John H. Glick, MD; Michael H. Veeder, MD; and James A. Mailliard, MD
[+] Article and Author Information

From the Mayo Clinic, Rochester, Minnesota. The Fred Hutchinson Cancer Research Center, Seattle, Washington. Temple University School of Medicine and the University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania. Grand Forks Clinic, Grand Forks, North Dakota. Ohio State University, Columbus, Ohio. St. Louis Community Clinical Oncology Program, St. Louis, Missouri. AMC Cancer Research Center, Denver, Colorado. Oncology Hematology Associates, Peoria, Illinois. St. Joseph Hospital and Creighton University Cancer Center, Omaha, Nebraska. Requests for Reprints: Janet Graff and Thomas R. Fleming, Southwest Oncology Group (SWOG-8591), Operations Office, 14980 Omincron Drive, San Antonio, TX, 78245. Acknowledgments: The authors thank Ms. Deborah Papenfus and Mr. John VanDamme, BS, BA, for data management and statistical assistance. Grant Support: In part by U.S. Public Health Service grants CA-25224, CA-31224, and CA-37404 (to the North Central Cancer Treatment Group and Mayo Clinic); CA-21115, CA-37403, and CA-39088 (to the Eastern Cooperative Oncology Group); CA-32102, CA-38926, and CA-3909 (to the Southwest Oncology Group); and CA-38926 (to the Fred Hutchinson Cancer Research Center) and by grants to individual participating institutions from the National Cancer Institute.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1995;122(5):321-326. doi:10.7326/0003-4819-122-5-199503010-00001
Text Size: A A A

Objective: To determine the effectiveness of two adjuvant therapy regimens in improving surgical cure rates in stage III (Dukes stage C) colon cancer.

Design: Randomized, concurrently controlled clinical trial.

Setting: Major cancer centers, universities, and community clinics affiliated with the North Cancer Treatment Group, the Southwest Oncology Group, and the Eastern Cooperative Oncology Group.

Patients: Those who had had curative-intent resections of stage III colon cancer in the previous 1 to 5 weeks.

Intervention: Patients were assigned to observation only, to levamisole alone (50 mg orally three times/d for 3 days, repeated every 2 weeks for 1 year), or to this regimen of levamisole plus fluorouracil (450 mg/m2 body surface area intravenously daily for 5 days and then, beginning at 28 days, weekly for 48 weeks).

Measurements: Rates of cancer recurrence and death. Early-and late-treatment side effects.

Results: With all 929 eligible patients able to be followed for 5 years or more (median follow-up, 6.5 years), fluorouracil plus levamisole reduced the recurrence rate by 40% (P < 0.0001) and the death rate by 33% (P = 0.0007). Levamisole reduced the recurrence rate by only 2% and the death rate by only 6%. With few exceptions, toxicity was mild and patient compliance was excellent. No evidence of late side effects was seen.

Conclusion: Fluorouracil plus levamisole is tolerable adjuvant therapy to surgery; it has been confirmed to substantially increase cure rates for patients with high-risk (stage III) colon cancer. It should be considered standard treatment for all such patients not entered into clinical trials.

Figures

Grahic Jump Location
Figure 1.
Recurrence-free interval according to treatment arm.

Patients who died without recurrence have been censored. 5-FU = fluorouracil.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Patterns of recurrence sites according to treatment arm.

Patients with more than one site are included in each involved recurrence site; patients who refused their treatment assignment are not included.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Survival according to treatment arm.

5-FU = fluorouracil.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)